547
Participants
Start Date
July 31, 2003
Primary Completion Date
October 31, 2007
Study Completion Date
October 31, 2007
Pioglitazone
Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
Glimepiride
Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
Birmingham
Phoenix
Huntington Beach
Los Angeles
Sacramento
San Diego
Torrance
Bridgeport
Farmington
Washington D.C.
Bay Pines
Jacksonville
Decatur
Boise
Chicago
Edgewood
Lexington
Louisville
New Orleans
Bangor
Baltimore
Detroit
Flint
Kalamazoo
Petoskey
Pontiac
Royal Oak
Ypsilanti
Duluth
Minneapolis
Saint Cloud
Columbia
Camden
Albany
Mineola
New York
Rochester
The Bronx
Troy
West Islip
Williamsville
Winston-Salem
Cincinnati
Cleveland
Columbus
Westlake
Oklahoma City
Tulsa
Abington
Bryn Mawr
Hershey
Pittsburgh
Providence
Greenville
Memphis
Oak Ridge
Amarillo
Houston
Lubbock
San Antonio
Charlottesville
Norfolk
Richmond
Everett
Green Bay
Ciudad de Buenos Aires
Córdoba
Quilmes
Edmonton
Vancouver
Victoria
Winnepeg
Saint John
London
Ottawa
Montreal
Sainte-Foy
Saskatoon
Santiago
Lead Sponsor
Takeda
INDUSTRY